

D2 antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region or a TNF-binding portion thereof and a human constant region.

4 94. (Amended) The method of Claim 91 wherein said anti-TNF chimeric antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, [4957] 49-57, or 155-157 of SEQ ID NO.: 1 of hTNF.

P3
P27 95. (Amended) A method of treating TNF α -mediated Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

6 96. (Amended) A method of treating TNF α -mediated Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody binds to one or more epitopes included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.

7 97. (Amended) A method of treating TNF α -mediated Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.

REMARKS

Claim Amendments

Claims 91, 94, 95, 96, and 97 have been amended. Claims 91, 95, 96 and 97 have been amended to recite a method of treating Crohn's disease which is TNF α -mediated. Claim 94 has been amended to correct a typographical error. Claim 96 has been